Roger M. Perlmutter, M.D., Ph.D., joined Merck in 2013 as the executive vice president and president of Merck Research Laboratories. He was formerly executive vice president and head of R&D at Amgen from January 2001 to February 2012. During his tenure, he oversaw the development and subsequent approval of a number of novel biologic and small molecule medicines in the areas of cancer, endocrinology, hematology, inflammation and osteoporosis.
Prior to joining Amgen, Dr. Perlmutter held roles of increasing responsibility at Merck Research Laboratories, culminating in his appointment to executive vice president of Worldwide Basic Research and Preclinical Development. He joined Merck as a senior vice president in February 1997. Most recently, he served as a director of several biotechnology companies and was a science partner at The Column Group, a biotechnology-focused venture capital firm.
Before assuming leadership roles in industry, Dr. Perlmutter was a professor in the Departments of Immunology, Biochemistry and Medicine at the University of Washington and also served as chairman of its Department of Immunology where he was a Howard Hughes Medical Institute investigator. His research focused on understanding the signaling pathways that control lymphocyte activation. Prior to this, he was a lecturer in the Division of Biology at the California Institute of Technology.
Dr. Perlmutter graduated from Reed College in Portland, Ore., and received his M.D. and Ph.D. degrees from Washington University in St. Louis, Mo. He completed his clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco.Dr. Perlmutter is a Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science.